Sort Results by

  1. Durata Therapeutics, Inc. Reports First Quarter 2013 Financial Results

    -Raised $54 million in Recent Equity Offering-

    GlobeNewswire via Yahoo! Finance May 9 11:00AM UTC

  2. Paul A. Friedman, M.D. is Elected to Durata Therapeutics' Board of Directors

    CHICAGO -- Durata Therapeutics today announced that Paul A. Friedman, M.D. was elected to its Board of Directors at the Company's 2013 Annual Meeting of Stockholders, which was held today. The Company ...

    GlobeNewswire via Yahoo! Finance May 16 17:44PM UTC

  3. New Data Demonstrating In Vitro Potency of Dalbavancin Against Bacterial Pathogens Presented at the 23rd Annual ECCMID ...

    CHICAGO -- Durata Therapeutics, Inc. today announced data from surveillance results of its lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure ...

    GlobeNewswire via Yahoo! Finance Apr 29 11:30AM UTC

  4. Durata Therapeutics to Present Two Dalbavancin Posters at the 23rd Annual ECCMID Meeting

    CHICAGO -- Durata Therapeutics, Inc. today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, will be presented in two posters at the 23rd Annual European ...

    GlobeNewswire via Yahoo! Finance Apr 24 11:30AM UTC

  5. Phase I Data Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of Dalbavancin Presented at ...

    CHICAGO -- Durata Therapeutics, Inc. today announced data from a Phase 1 study of its lead product candidate, dalbavancin, under investigation for the treatment of susceptible gram positive bacterial infections ...

    GlobeNewswire via Yahoo! Finance Apr 29 11:30AM UTC